Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insite Vision Inc. -- Ignore unavailable to you. Want to Upgrade?

To: DGMontana who wrote (829)	8/19/1998 10:42:00 AM
From: Purpleman	Respond to of 1060

"Insite Vision spiked on the news that it hired Paine Webber to 'evaluate opportunities' several weeks ago. It traded back down to its pre-announcement price on no news. After considerable research on our behalf by a third party consultant, we do not believe you will see a buyout of the company. Rather, negotiations are ongoing to sign on a major partner for the glaucoma screening technology. ISV now has a kit for use by physicians to catch glaucoma in its earliest stages. We expect a deal any day, but keep in mind that these sorts of negotiations sometimes stretch out for a much longer period than anticipated. This deal, when and if it is signed, will be for major dollars and should make Insite profitable in 1999."

To: DGMontana who wrote (829)	8/19/1998 11:56:00 AM
From: Robert Mayo	Read Replies (1) \| Respond to of 1060

"How close to the edge are they?" According to the CEO, cash will be OK through December at least. A deal, any deal, will bring some up-front cash payments that will alleviate the problem immediately. As I've said before on this board, my best guess is before the end of September. Unfortunately, like Murphy, my estimates have been wrong before, so use your own judgment. Two things that lend a bit more credibility to prognostications that, finally, a deal, or deals, will get done, is the hiring of Paine Webber and the Board's refusal to let management dilute again. This is turning into a nail biter though. Bob